Bispecific antibodies paired with cytotoxic drugs eliminated tumors in laboratory mice and trained their immune systems to reject returning cancer cells, researchers from Regeneron Pharmaceuticals reported in Nature Communications. The preclinical study evaluated whether combining targeted cell-killing therapies with immune-stimulating molecules could build lasting antitumor memory. In test models, animals that cleared breast tumors resisted reinfection four weeks later without extra medication. While standard cytotoxic treatments often trigger drug resistance or serious side effects, this dual approach activated protective T cells and lowered required doses [1].
How Bispecific Antibodies Guide T Cells
Standard cancer therapies destroy malignant cells through direct toxicity, yet tumors frequently escape treatment by mutating or exhausting the body’s natural defenses. An effective immune response relies heavily on killer T cells, but these white blood cells need two distinct chemical signals to mount a sustained attack against cancer. They must first recognize a target protein on the malignant cell surface and then receive a secondary co-stimulatory prompt through an activation receptor known as CD28. Without that second signal, T cells often become inactive or fail to multiply within the hostile tumor environment. To evaluate this mechanism accurately in animal models, researchers genetically modified mice so their immune cells displayed human CD28 receptors [2].
To bridge this gap, Regeneron scientists created bispecific antibodies designed to attach to two different targets at once. One end binds an antigen on cancer cells, while the other end grabs CD28 on T cells. The team tested versions targeting two growth proteins, HER2 and EGFR, in mice carrying humanized CD28 receptors along with modified tumor targets. For HER2 and EGFR, the outer exposed portions of the target proteins were human, while the membrane-spanning segments remained mouse [1].
Complete Tumor Clearance in Mice
Researchers paired their bispecific construct with trastuzumab deruxtecan, an antibody-drug conjugate sold commercially as Enhertu. The medication joins a monoclonal antibody directed at HER2 with a chemical payload that kills dividing cells, delivering toxic compounds to tissue that overexpresses the growth factor. Enhertu works by binding to cells displaying HER2 and releasing deruxtecan, a topoisomerase I inhibitor that damages cancer cell DNA. Doctors already prescribe Enhertu for certain human breast, gastric, and other cancers, but tumors routinely build resistance after several treatment cycles. In preliminary laboratory tests on mice bearing aggressive breast tumors, Enhertu monotherapy produced complete remission in fewer than half the subjects, even when given at the highest experimental dose [1].
Adding the HER2-targeted bispecific molecule shifted the response. The combination wiped out breast tumors in all nine treated mice. Every animal remained tumor-free through the observation period, whereas mice receiving either agent alone suffered progressive tumor growth or experienced only partial tumor shrinkage before disease returned [2].
Lasting Immune Memory Against Recurrence
The most striking evidence appeared after the nine cured mice had lived without tumors for at least four weeks. To test whether the animals had developed lasting biological protection, researchers injected fresh cells from the original breast cancer line back into the animals without administering any further medication. The mice rejected the challenge and never developed secondary growths. When the team depleted CD8+ T cells from the animals, the protective shield disappeared and tumors grew rapidly. This test proved that CD8+ killer T cells served as the primary drivers of long-term immune protection [1].
Did the animals remember the shared protein or the original tumor? To answer that question, investigators introduced colorectal cancer cells that also expressed HER2 into the recovered mice. If the immune cells only recognized HER2, they should have destroyed the colon cancer cells as well. Instead, the colorectal tumors grew unchecked in the host animals. This differential response showed that the immune system had memorized a complex collection of tumor features from the first cancer, rather than reacting solely to the engineered surface antigen used during treatment. The experimental data indicated that the combination therapy generated a polyclonal antitumor T cell response capable of targeting diverse cancer neoantigens [2].

Testing Bispecific Antibodies with Chemotherapy
The research group next tested whether the principle applied to other cancer targets and conventional chemotherapies. They built an experimental bispecific antibody targeting epidermal growth factor receptor, or EGFR, a growth-related protein found on many epithelial tumors. This EGFR drug candidate is already undergoing early-stage phase 1/2 clinical trials in human cancer patients. In mice with breast tumors that resisted Enhertu alone, combining Enhertu with the EGFR-directed bispecific antibody produced complete tumor rejection in approximately 75 percent of the animals, showing that the strategy worked across distinct tumor antigens and challenging disease models [1].
The scientists also paired the EGFR molecule with 5-fluorouracil, an antimetabolite chemotherapy known as 5-FU that is widely used against colorectal cancer. Fluorouracil functions by blocking thymidylate synthase, starving rapidly dividing tumor cells of the pyrimidine nucleotides necessary for DNA synthesis. In difficult colorectal tumor models, neither 5-FU nor the antibody stopped tumor growth on its own. Giving both drugs together noticeably slowed tumor progression. This chemotherapy combination required both CD8+ T cells and natural killer cells, keeping some antitumor activity if one group remained but failing if both cell populations were absent [2].
Dendritic Cells and Receptor Diversity
To learn how the drug pairings altered host biology, the authors analyzed cellular activity and gene expression inside the treated tumors. They discovered that different cytotoxic agents stimulated the immune system through separate cellular mechanisms. Enhertu activated conventional dendritic cells, which are specialized immune scouts that collect tumor debris and present target fragments to resting T cells. When the authors tested genetically engineered mice that lacked this dendritic cell subpopulation, the Enhertu and antibody combination lost its antitumor effect completely, confirming that dendritic cells were essential [2].
Chemotherapy with 5-FU acted on a separate cellular pathway. Rather than recruiting dendritic cells, 5-FU shifted myeloid cell populations into an attacking state and reduced regulatory cells that usually suppress immune responses within tumor tissue. Both drug pairings preserved a population of stem-like CD8+ T cells and widened the diversity of T cell receptors, allowing the immune army to recognize multiple tumor mutations instead of exhausting itself on a single target [1].
Human Limitations and Dosing Potential
Because the dual therapy produced stronger immune stimulation, researchers could lower drug doses or administer chemotherapy less frequently while maintaining tumor control in mice. Reducing dosage could offer real relief in human cancer clinics, where high doses of cytotoxic drugs often trigger toxic side effects that force doctors to pause care. However, mouse models cannot replicate the full spectrum of adverse events that human patients experience, such as potential damage to the lungs, heart, skin, and gastrointestinal tract [1].
Regeneron Pharmaceuticals funded the project, and all study authors are current or former employees of the biotechnology company. In addition, provisional patent applications covering the dual-treatment methods have been filed with patent authorities. Clinical trials in human oncology patients will now be required to determine whether bispecific antibodies and chemotherapy can safely replicate these antitumor responses and durable immune memories in clinical practice [2].
- ONLINE NEWS Öz, E. (2026). Experimental Drug Combination Cleared Tumors in Mice And Left Them Resistant to The Same Cancer. ScienceAlert. [Article Link]
- ACADEMIC JOURNAL Kwart, D., Wei, Q., Cheng, W., Ryan, K., Leary, A., Golubov, J., Torres, C., Poon, P., Warsaw, J., Lowy, J., Ullman, E., Hermann, A., Finney, J., Haber, L., Canturri, A., Ajithdoss, D., Skinner, A., Smith, E., Daly, C., & Ni, M. (2026). Cytotoxic drugs and bispecific T cell engagers synergize to rewire host immunity and elicit polyclonal antitumor T cell responses. Nature Communications. [Article Link]
APA 7: PerEXP Teamworks. (2026, November 22). Regeneron Pairs Bispecific Antibodies with Chemo to Clear Tumors. PerEXP Teamworks. https://perexpteamworks.com/en/bispecific-antibodies-clear-mouse-tumors/